2020-05-09
FDA Approves Selpercatinib for RET+ Lung and Thyroid Cancers
The FDA has approved selpercatinib (formerly known as LOXO-292; Retevmo™) capsules for the treatment of patients with lung cancer or thyroid cancer harboringRETalterations.This marks the first treatment approved to targetRETgene alterations.
Contact

Address

Office: Philadelphia, US

Office: Building 10-1, No.2 Jingyuan North Street, BDA, Beijing, China

Tel

+1-484-222-1342 +86-10-67860673

Mobile Mode
Copyright © 2022 All Rights Reserved Applied Pharmaceutical Science
Terms of Use

Loading...

Privacy policy

Loading...